Sharekhan

#SharekhanResearch retains Buy rating on #Biocon(PT Rs 420); inks deal with Viatris’ to buy its biosimilar assets,… https://t.co/IRgfT0uLW8 #SharekhanResearch #Biocon

#SharekhanFNA #SharekhanResearch retains Buy rating on #Biocon(PT Rs 470) #Q3FY22 rev & PAT clock double digit gwth… https://t.co/YPiAq1MWaz #SharekhanFNA #SharekhanResearch #Biocon #Q3FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #Biocon(PT Rs 470) #Q2FY22 was healthy qtr; reducing impact… https://t.co/2GLe8j9M4p #SharekhanFNA #SharekhanResearch #Biocon #Q2FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #Biocon(PT Rs 470) #Q1FY22 was a weak qtr & results missed e… https://t.co/iEpiyfAKtx #SharekhanFNA #SharekhanResearch #Biocon #Q1FY22

#SharekhanResearch retains Buy rating on #Biocon (PT Rs 470) #Q4FY21 was a weak qtr; Biologics to be key growth dri… https://t.co/Nd8ghOCRGT #SharekhanResearch #Biocon #Q4FY21

#SharekhanFNA #SharekhanResearch retains Buy recommendation on #Biocon (PT Rs 520); Expected traction in existing b… https://t.co/FfRjqyX97f #SharekhanFNA #SharekhanResearch #Biocon

#SharekhanFNA #USFDA has informed #Biocon of deferred action for its Biologics License Appln for proposed biosimila… https://t.co/BTzX75S0AZ #SharekhanFNA #USFDA #Biocon

#SharekhanFNA #SharekhanResearch retains Positive view on #Biocon (upside 18-20%); Biologics segment to be a key dr… https://t.co/1TgKlS4GT9 #SharekhanFNA #SharekhanResearch #Biocon

#SharekhanFNA #SharekhanResearch retains Positive view on #Biocon (upside potential 18-20%); to be a beneficiary of… https://t.co/6TBzix3yjV #SharekhanFNA #SharekhanResearch #Biocon